The principal performance objective of the Colorado Autoimmunity Center of Excellence (Colorado ACE) Administrative Core (Core A) is to facilitate the smooth operation of the Center, and establish an integrated and dynamic collaborative clinical research program that contributes significantly to the overall mission of the ACE consortium. This will be achieved by ensuring effective communication between its members, efficient fiscal and regulatory management, appropriate distribution of resources, timely preparation and submission of all reports, rapid implementation of new ideas and improved procedures, and by providing beneficial academic enrichment. The Core aims to promote and foster synergy and collaboration between the clinical and basic research programs both within the Center, and wider ACE Consortium, and to remove any barriers that could impede fulfillment of the core mission of the ACE program to accelerate the translation of research findings from the bench to the clinic. Activities that the Core will pursue/support will include: ' Formation of an Executive Committee drawn from key members of the Colorado ACE and other local experts in clinical, basic, and/or translational immunology that will meet quarterly to provide regular oversight and a forum for problem identification and resolution. ' Formation of an External Advisory Board that will meet annually to provide additional oversight, and also contribute to the establishment and maintenance of a strong collaborative environment that has both internal and external components. ' Provision of an interface between the Colorado ACE and the central Steering Committee of the ACE consortium, with the goal of achieving effective bi-directional communication of recommendations and ideas between the External Advisory Board, local Executive Committee, central Steering Committee and individual ACE members. ' Management of all regulatory and fiscal responsibilities related to the Center Grant. ' Provision of administrative support for Clinical Project Development ' Provision of academic enrichment for members of the Center. This will involve organization and support of seminars and journal clubs relevant to autoimmunity, and organization of an annual workshop devoted to Autoimmune Disease.

Public Health Relevance

The Colorado Autoimmunity Center of Excellence that this Core supports will develop and test innovative therapies for multiple autoimmune diseases; which together afflict up to 8% of the total US population. The Administrative Core will provide oversight and management of the Center and is essential to its functioning effectively.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI110503-02
Application #
8842277
Study Section
Special Emphasis Panel (ZAI1-PA-I)
Project Start
Project End
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
2
Fiscal Year
2015
Total Cost
$77,708
Indirect Cost
$27,708
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Michels, Aaron W; Gottlieb, Peter A (2018) Learning From Past Failures of Oral Insulin Trials. Diabetes 67:1211-1215
Sparks, Jeffrey A; Iversen, Maura D; Yu, Zhi et al. (2018) Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial. Arthritis Care Res (Hoboken) 70:823-833
Ostrov, David A; Alkanani, Aimon; McDaniel, Kristen A et al. (2018) Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest 128:1888-1902
Kowarik, Markus C; Astling, David; Gasperi, Christiane et al. (2017) CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol 4:369-380
Deane, Kevin D; Striebich, Christopher C; Holers, V Michael (2017) Editorial: Prevention of Rheumatoid Arthritis: Now Is the Time, but How to Proceed? Arthritis Rheumatol 69:873-877
Peschl, Patrick; Schanda, Kathrin; Zeka, Bleranda et al. (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation 14:208
Shimizu, Fumitaka; Schaller, Kristin L; Owens, Gregory P et al. (2017) Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med 9:
Soltys, John N; Meyer, Stephanie A; Schumann, Hannah et al. (2017) Determining the Spatial Relationship of Membrane-Bound Aquaporin-4 Autoantibodies by STED Nanoscopy. Biophys J 112:1692-1702
Vogel, Anna-Lena; Knier, Benjamin; Lammens, Katja et al. (2017) Deletional tolerance prevents AQP4-directed autoimmunity in mice. Eur J Immunol 47:458-469
Liu, Yiting; Given, Katherine S; Harlow, Danielle E et al. (2017) Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol Commun 5:25

Showing the most recent 10 out of 24 publications